Literature DB >> 19501164

The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.

Arnar Astradsson1, Bruce G Jenkins, Ji-Kyung Choi, Penelope J Hallett, Michele A Levesque, Jack S McDowell, Anna-Liisa Brownell, Roger D Spealman, Ole Isacson.   

Abstract

It has been suggested, based on rodent studies, that levodopa (L-dopa) induced dyskinesia is associated with a disrupted blood-brain barrier (BBB). We have investigated BBB integrity with in vivo neuroimaging techniques in six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned primates exhibiting L-dopa-induced dyskinesia. Magnetic resonance imaging (MRI) performed before and after injection of Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) revealed an intact BBB in the basal ganglia showing that l-dopa-induced dyskinesia is not associated with a disrupted BBB in this model.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19501164      PMCID： PMC3319396          DOI： 10.1016/j.nbd.2009.05.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN： 0969-9961            Impact factor:   5.996


  23 in total

1.  Pharmacokinetic modeling of Gd-DTPA extravasation in brain tumors.

Authors:  Lutz Ludemann; Reinhard Wurm; Claus Zimmer
Journal:  Invest Radiol       Date:  2002-10       Impact factor: 6.016

Review 2.  Levodopa in the treatment of Parkinson's disease: current controversies.

Authors:  C Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; Ubaldo Bonuccelli; U Bonucelli; Philip Damier; Justo De Yebenes; Oscar Gershanik; Mark Guttman; F Grandas; Mark Hallett; Ole Hornykiewicz; Peter Jenner; R Katzenschlager; William J Langston; Peter LeWitt; Eldad Melamed; M A Mena; P P Michel; Catherine Mytilineou; Jose A Obeso; Werner Poewe; Niall Quinn; R Raisman-Vozari; Ali H Rajput; Olivier Rascol; Christina Sampaio; Fabrizio Stocchi
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

3.  The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury.

Authors:  A Beaumont; A Marmarou; K Hayasaki; P Barzo; P Fatouros; F Corwin; C Marmarou; J Dunbar
Journal:  Acta Neurochir Suppl       Date:  2000

4.  Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey.

Authors:  C Imbert; E Bezard; S Guitraud; T Boraud; C E Gross
Journal:  J Neurosci Methods       Date:  2000-03-01       Impact factor: 2.390

Review 5.  Preventing levodopa-induced dyskinesias.

Authors:  C W Olanow; J A Obeso
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

Review 6.  Description of Parkinson's disease as a clinical syndrome.

Authors:  Stanley Fahn
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

7.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

Authors:  Erwan Bézard; Sandrine Ferry; Ulrich Mach; Holger Stark; Ludovic Leriche; Thomas Boraud; Christian Gross; Pierre Sokoloff
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

8.  MRI measurement of blood-brain barrier permeability following spontaneous reperfusion in the starch microsphere model of ischemia.

Authors:  Neil G Harris; Victoria Gauden; Paul A Fraser; Stephen R Williams; Geoff J M Parker
Journal:  Magn Reson Imaging       Date:  2002-04       Impact factor: 2.546

9.  Future of cell and gene therapies for Parkinson's disease.

Authors:  Ole Isacson; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

10.  Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

Authors:  Bruce G Jenkins; Rosario Sanchez-Pernaute; Anna-Liisa Brownell; Yin-Ching Iris Chen; Ole Isacson
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.709
View more
  15 in total

1.  Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.

Authors:  Lissa S Brod; Jason L Aldred; John G Nutt
Journal:  Mov Disord       Date:  2012-04-16       Impact factor: 10.338

Review 2.  Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.

Authors:  Oliver Cooper; Arnar Astradsson; Penny Hallett; Harold Robertson; Ivar Mendez; Ole Isacson
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

3.  Development of histocompatible primate-induced pluripotent stem cells for neural transplantation.

Authors:  Michela Deleidi; Gunnar Hargus; Penelope Hallett; Teresia Osborn; Ole Isacson
Journal:  Stem Cells       Date:  2011-07       Impact factor: 6.277

4.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

5.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

Review 6.  Effects of levodopa on regional cerebral metabolism and blood flow.

Authors:  Ji Hyun Ko; Renata P Lerner; David Eidelberg
Journal:  Mov Disord       Date:  2014-10-09       Impact factor: 10.338

7.  Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

Authors:  K Elisabet Ohlin; Veronica Francardo; Hanna S Lindgren; Stephanie E Sillivan; Sean S O'Sullivan; Andrew S Luksik; Fair M Vassoler; Andrew J Lees; Christine Konradi; M Angela Cenci
Journal:  Brain       Date:  2011-07-19       Impact factor: 13.501

Review 8.  Neuroinflammation in Parkinson's disease.

Authors:  Jae-Kyung Lee; Thi Tran; Malú G Tansey
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-10       Impact factor: 4.147

9.  Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Authors:  Maria Sundberg; Helle Bogetofte; Tristan Lawson; Johan Jansson; Gaynor Smith; Arnar Astradsson; Michele Moore; Teresia Osborn; Oliver Cooper; Roger Spealman; Penelope Hallett; Ole Isacson
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

10.  L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain.

Authors:  M Y Inyushin; A Huertas; Y V Kucheryavykh; L Y Kucheryavykh; V Tsydzik; P Sanabria; M J Eaton; S N Skatchkov; L V Rojas; W D Wessinger
Journal:  Parkinsons Dis       Date:  2012-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.